Meeting
2021 ASCO Annual Meeting
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).
Authors
Kim van der Zande
Netherlands Cancer Insitute, Amsterdam, Netherlands
Kim van der Zande , Vincent van der Noort , Milou Busard , Paul Hamberg , Suzan Ras - van Spijk , Jeantine De Feijter , Vincent O. Dezentjé , Metin Tascilar , Danny Houtsma , Aart Beeker , H Pieter van den Berg , Diederik ten Oever , Irma M. Oving , Wilbert Zwart , Andre M. Bergman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03295565
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5059)
DOI
10.1200/JCO.2021.39.15_suppl.5059
Abstract #
5059
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
First Author: Edoardo Francini
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2021 Genitourinary Cancers Symposium
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
First Author: Johann S. De Bono
Poster
2019 Genitourinary Cancers Symposium
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
First Author: Cecile Vicier